An experimental drug that restored the normal function of ion channels in Alzheimer's disease (AD) prevented the loss of neurons and reduced the accumulation of amyloid-β (Aβ) plaques and hyperphosphorylated tau formed in this condition. A new class of small molecules, collectively called ReS19-T and developed by scientists at the Belgian biotechnology company Remynd NV, reorganized proteins that modulated calcium channels. Now in the clinical phase, this approach could benefit patients suffering from neurodegenerative disorders. Read More
Excessive inflammatory response and endothelial barrier dysfunction are the two major pathophysiological changes in acute respiratory distress syndrome (ARDS). Sphingosine-1-phosphate S1P3 receptor (S1PR3) is a G protein-coupled receptor involved in the regulation of inflammation and vascular barrier function in some diseases, but its function in ARDS is not fully understood. Read More
Ovarian cancer stem cells are characterized by high activity of aldehyde dehydrogenase (ALDH) enzyme as well as high expression of CD133 marker, and the combination of both correlates with poor prognosis in patients. Read More
Alchemab Therapeutics Ltd. has been awarded a grant of $595,000 by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support its Parkinson’s disease program. Read More
Nutcracker Therapeutics Inc. has disclosed a new drug candidate for the treatment of B-cell lymphoma – NTX-472 – along with results from in vivo studies performed to evaluate its efficacy in mice and macaques. Read More
University of Basel investigators have reported an association between mutations in the COQ8B gene and nonsyndromic retinitis pigmentosa (RP). RP is a genetically heterogeneous retinal degeneration disorder, which has been found to be associated with mutations in more than 70 genes. However, there are still cases for which no genetic cause has been found. Read More
Scientists at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, Suzhou Vigonvita Life Sciences Co. Ltd. and The Xinjiang Technical Institute of Physics & Chemistry of the Chinese Academy of Sciences have disclosed NMDA receptor antagonists reported to be useful for the treatment of neurological disorders. Read More
Ribometrix Inc. has synthesized eukaryotic translation initiation factor 4E (eiF4E) inhibitors reported to be useful for the treatment of cancer, fibrosis, inflammatory disorders and allergy. Read More
Patients with type 1 diabetes have reduced functional pancreatic β-cell mass due to cytokine-induced β-cell death and inflammatory cell infiltration. Read More
Nikang Therapeutics Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a cyclin-dependent kinase 2 (CDK2) targeting moiety through a linker reported to be useful for the treatment of cancer. Read More
Scientists at Korea Research Institute of Chemical Technology and Oncord Bio Inc. have divulged molecular glue degraders targeting protein cereblon (CRBN) and acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers reported to be useful for the treatment of cancer, graft-vs.-host disease, leprosy and inflammatory disorders. Read More
KRAS is the most commonly mutated oncogene in solid tumors. Mutations are present in about 30% of cases overall, more than 95% of pancreatic cancer cases, and about 40% of colon cancer cases. Read More
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has described serine/threonine-protein kinase ULK1 inhibitors reported to be useful for the treatment of cancer. Read More
Relay Therapeutics Inc. has disclosed three new programs from its existing preclinical pipeline, including two novel programs from its genetic disease portfolio and a potentially first-in-class NRAS-selective inhibitor. Read More
Valanx Biotech GmbH has reported promising in vivo results for its lead program, VLX-101, for the treatment of a wide range of autoimmune diseases. Read More
